Abstract
LAI antipsychotics have been available to providers for more than 40 years yet they appears to be underutilized. LAI second-generation antipsychotics have been well-studied in clinical situations and in regulatory trials their adverse effects are well understood. LAI antipsychotics offer providers a viable option to help with medication adherence and reduce any potential gaps in treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 31-34 |
| Number of pages | 4 |
| Journal | Psychiatric Times |
| Volume | 37 |
| Issue number | 3 |
| State | Published - Mar 2020 |